Anondita MedicareShare price, financial results, shareholding and management

NSE Emerge · ANONDITACondom manufacturingListed 1 Sept 2025IPO ₹145Catch them young
anonditamedicare.com ↗Live price on NSE ↗ISIN INE0VTV01012 · Lot 200 shares · ₹2.08 lakh
₹1,038.45
-2.00% on the day
Close · 19 Nov 2026
Valuation
Market cap
₹1,978 cr
Stock P/E
57.7peers 15.1
Book value
₹67.9
Price to book
15.29
EV / operating profit
39.5
Market cap to sales
14.39
Returns and growth
ROCE · FY26
44.5%
ROE · FY26
41.3%
ROE, 3-year average
41.3%
Operating margin · FY26
36.9%peers 14.0%
Sales growth, 3 years
+78.5%
Profit growth, 3 years
+114.4%
Safety
Debt to equity
0.26peers 0.14
Borrowings
₹33.6 cr
Interest cover
14.2×
Cash from business / op. profit
21%
Debtor days
138
Pledged
0.00%
Ownership and share
Promoter holding
59.26%
Change in promoter holding
-3.14 pts
Shareholders
2,070
52-week high / low
₹1,316 / ₹602
Dividend yield
0.00%
Face value
₹10

Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.

Anondita Medicare share price chart

₹1,038.45+60.40% 1 year

Close on 19 Nov 2026 · -1.97% on the day · Vol 17,100

Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.

Share price returns

To the close of 19 Nov 2026

1 month
+3.1%
3 months
-3.4%
6 months
-2.6%
1 year
+60.4%
Since IPO
+616.2%
Traded a day, 20 days
₹5.33 cr
Taken for delivery
70%

Business growth

Sales and net profit, from the reported results

SalesProfit
FY26 on FY25+78%+114%
3 years, a year--
Latest half, H2 FY26+81%+113%

About Anondita Medicare: business, products and customers

Anondita Medicare makes condoms at its own plant in Noida and sells them under its own brand, Cobra, to shops in several states and to government health programmes. Its shares trade on NSE Emerge.

Anondita Medicare makes male condoms at its plant in Noida, Uttar Pradesh, and sells them under its own brand, COBRA, in flavours such as strawberry, mint, chocolate and coffee. Every condom is tested electronically, and the company prints and packs in house. It also supplies condoms to government buyers such as the Central Medical Services Society for the family planning programme.

The business began in 1999 as a proprietorship of Anupam Ghosh that packed and sold condoms and gloves; it started making condoms in 2004 and for years made them for other brands, including Mankind Pharma's Manforce. The company was formed in March 2024 to take over that business and bought the subsidiary Anondita Healthcare and Rubber Products India Limited, which sells COBRA products along with gloves, pregnancy test kits and other wellness items. The shares listed on NSE Emerge on 1 September 2025.

Read more about the business

Revenue from operations was ₹137.4 cr in FY26; the chief financial officer said on the May 2026 call that about ₹118 cr came from condoms and about ₹19 cr from gloves, and that about 42% of sales went to government buyers. The chief financial officer also said government payments take at least 120 days, and trade receivables stood at ₹51.9 cr at March 2026.

Capacity rose to 869 million pieces a year after 307 million pieces were added on 23 February 2026, and more lines are on trial or being built. The company reports trial production of female condoms in latex and non latex, MDSAP and SABS certificates for selling abroad, and trial export orders from a partner in Kenya.

From the offer document, the 2025-26 annual report, the June 2026 investor presentation and the May 2026 earnings call.

Read the deeper study ↓

In its favour

  • Sales have grown very fast: 78% a year last year.
  • It earns a high return on the money it uses: ROCE 45% in FY26.
  • It has little debt for its size: debt to equity 0.26.

To watch

  • Four new lines on trial and four more being built, due by January 2027 (Annual report 2025-26, p.13).
  • The South African government supply: approved for five years, with the purchase order still pending at the May 2026 call (Earnings call transcript, May 2026, p.8).
  • Supply under the Central Medical Services Society family planning tender for 8,00,62,000 condoms, where the company was declared L1 in August 2026 (Press release, September 2026, p.2).
  • UN qualification for exports, still pending at the May 2026 call (Earnings call transcript, May 2026, p.9).
  • The promoters' share has come down: 59.26%, from 61.79%.

From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.

Anondita Medicare revenue and profit growth

Half-yearly results · Profit and loss

Sales have grown very fast. Last year profit grew faster than sales, so the company kept more from each rupee of sales.

Sales and net profit, every year, ₹ crore
SalesNet profit
050100150Sales, FY25: 77 ₹ cr77Net profit, FY25: 16 ₹ cr16FY25Sales, FY26: 137 ₹ cr137Net profit, FY26: 34.3 ₹ cr34.3FY26
The latest halves, ₹ crore
SalesNet profit
0255075100Sales, H1FY25: 31 ₹ cr31Net profit, H1FY25: 6 ₹ cr6H1FY25Sales, H2FY25: 46 ₹ cr46Net profit, H2FY25: 10 ₹ cr10H2FY25Sales, H1FY26: 54.1 ₹ cr54.1Net profit, H1FY26: 13 ₹ cr13H1FY26Sales, H2FY26: 83.3 ₹ cr83.3Net profit, H2FY26: 21.3 ₹ cr21.3H2FY26

SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew faster than sales.

Anondita Medicare half-yearly results

SME companies report every six months · ₹ crore

₹ crore · growth on the same half a year before
H1FY25H2FY25H1FY26H2FY26
Sales314654.1083.32
Expenses223034.9051.85
Operating profit101619.2031.46
OPM31.0%35.0%35.5%37.8%
Interest111.821.71
Depreciation000.410.67
Profit before tax81417.3829.51
Net profit61013.0221.28

Anondita Medicare profit and loss

Full years to March, FY25 to FY26 · ₹ crore, consolidated where reported

₹ crore
FY25FY26
Sales77137.42
Expenses5186.75
Operating profit2650.67
OPM33.0%36.9%
Other income00.84
Interest33.54
Depreciation11.08
Profit before tax2246.89
Tax rate27.3%26.9%
Net profit1634.30
EPS ₹11.3421.30
Dividend payout0.0%0.0%

The years to FY25 come rounded to the nearest crore in the source.

Anondita Medicare profitability

Margins and returns on capital

Last year the company kept more from each rupee of sales than the year before. It earns a high return on the money it uses.

Operating margin, every year

Per cent of sales kept before interest, depreciation and tax

0%20%40%60%FY25: 33.0%33.0%FY25FY26: 36.9%36.9%FY26
Per cent
FY25FY26
Operating margin33.0%36.9%
Tax rate27.3%26.9%
ROCE·44.5%
ROE·41.3%
Dividend payout0.0%0.0%

Anondita Medicare debt and cash flow

Balance sheet · Cash flow · Working capital

The company's own money, its net worth, has grown fast. Its loans are smaller than its own money. Last year the business brought in less cash than it showed as profit, so part of the profit is still to be collected. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take about as long to pay as they did in FY25.

Its own money and its borrowings, ₹ crore
Net worthBorrowings
050100150Net worth, FY25: 37 ₹ cr37Borrowings, FY25: 27 ₹ cr27FY25Net worth, FY26: 129 ₹ cr129Borrowings, FY26: 33.6 ₹ cr33.6FY26
Cash from the business against net profit, ₹ crore
Cash from the businessNet profit
-2002040Cash from the business, FY25: -7 ₹ cr-7Net profit, FY25: 16 ₹ cr16FY25Cash from the business, FY26: 10.6 ₹ cr10.6Net profit, FY26: 34.3 ₹ cr34.3FY26

Bars below the line are cash going out.

Anondita Medicare balance sheet

At each 31 March · ₹ crore

₹ crore
FY25FY26
Equity capital1318.09
Reserves24111.15
Net worth37129.24
Borrowings2733.60
Other liabilities1321.99
Total liabilities77184.83
Fixed assets1339.29
Capital work in progress642
Investments33.31
Other assets55100.23
Receivables·51.86
Inventory·20.75
Cash·9.65
Trade payables·8.03

Anondita Medicare cash flow

₹ crore

₹ crore
FY25FY26
Cash from operations-710.64
Cash from investing-19-62.70
Cash from financing2661.28
Net cash flow09.22
Capital spending·62.81

Working capital

Days

Days
FY25FY26
Debtor days127138
Inventory days128125
Days payable3648
Cash conversion cycle218214
Working capital days129163

Anondita Medicare peers and competitors

Listed SME companies in the same industry

By sales, Anondita Medicare is number 1 of the 8 listed SME companies in personal products.

Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.

CompanyMarket cap ₹ crP/ESales ₹ crProfit ₹ crOp. marginDebt/equity
Anondita Medicare1,97857.713734.336.9%0.26
H. R. Hygiene Products13912.61301114.0%0.51
Recode Studios48644.2801121.0%0.30
Medistep Healthcare294.970.8611.6%0.14
Aakaar Medical Technologies10115.1676.615.4%0.34
Macobs Technologies19567.241.42.98.3%0.06
Ravelcare6813.1275.226.2%0.00
Novateor Research Laboratories23227.03.80.1-2.6%0.09
Median of the 7 others10115.167614.0%0.14

Anondita Medicare shareholding pattern

Promoters, FIIs, DIIs, HNIs and small holders

The promoters own more than half the company, a little less than in the first filing shown. Foreign and Indian funds own a noticeable share. The number of shareholders has grown a lot.

Promoters
59.26%
-2.53 pts since Sep 25
Foreign investors (FIIs)
2.48%
-1.76 pts since Sep 25
Indian institutions (DIIs)
6.05%
-0.50 pts since Sep 25
HNIs (over ₹2 lakh each)
13.59%
+3.51 pts since Sep 25
Small holders (up to ₹2 lakh)
8.08%
+1.04 pts since Sep 25
Companies and others
10.54%
+0.24 pts since Sep 25
Number of shareholders
2,070
621 in Sep 25

Anondita Medicare shareholding pattern

Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.

Sep 25Mar 26Sep 26
Promoters61.79%62.40%59.26%
Foreign investors (FIIs)4.24%3.40%2.48%
Indian institutions (DIIs)6.55%5.70%6.05%
HNIs (over ₹2 lakh each)10.08%13.12%13.59%
Small holders (up to ₹2 lakh)7.04%5.73%8.08%
Companies and others10.30%9.65%10.54%
Number of shareholders6215302,070

The named holders are at 24 Sept 2026, beside 31 March 2026, each under the group the pattern files them in.

Anondita Medicare study: the business from its own documents

Read from 15 of the company's own documents

Anondita Medicare so far

From the company's own record

  1. 1 Sept 2025Listed on NSE Emerge at ₹145
  2. 24 Sept 2026Promoters at 59.26%
  3. 24 June 2026Highest close since listing, ₹1,233.15

Anondita Medicare key facts from the filings

Each figure with the document it comes from

Production capacity
869 million pieces
Condoms the Noida plant can make in a year, up from 562 million after 307 million pieces were added on 23 February 2026.Investor presentation, June 2026, p.11
Production in FY26
432 million pieces
Condoms made in FY26, against 259 million in FY25.Annual report 2025-26, p.10
Lines being added
4 on trial, 4 being built
Four lines of about 250 million pieces a year are on trial and four more are being built, due by January 2027, the managing director says.Annual report 2025-26, p.13
Government share of sales
About 42%
Share of FY26 sales made to government buyers; the rest came mostly from the company's own brand, the chief financial officer said.Earnings call transcript, May 2026, p.12
Government tender
80.1 million pieces
Declared the lowest bidder (L1) in August 2026 in a Central Medical Services Society tender to supply 8,00,62,000 condoms for the family planning programme.Press release, September 2026, p.2
Show 3 more facts
Retail reach
4,569 retailers
Served through 26 super stockists and 195 distributors across eight states and regions, including Maharashtra, West Bengal and Rajasthan.Investor presentation, June 2026, p.15
Export certificates
MDSAP and SABS
MDSAP certification in November 2025 covers selling in Australia, Brazil, Canada, Japan and the United States; SABS certification covers male condoms for South Africa.Annual report 2025-26, p.13 and p.11
Credit rating
BWR BBB/Stable
Brickwork Ratings rated ₹56.2 cr of bank loans in May 2026, noting the promoter centred management and working capital tied up in long credit periods.Credit rating note, May 2026, p.2

What the company said, and what happened

The company's own statements, attributed, set against what it later reported; not newboard's estimates

The company says it is targeting revenue growth of 60 to 70% by FY27 with an EBITDA margin of about 30%, and an export share of 25% by FY27. On the May 2026 call the managing director said the South African government had approved the company to supply for five years, with the purchase order still pending. A June 2026 press release says the company is targeting ₹1,000 cr of revenue in the next two years. These are the company's statements, not newboard's.

60 to 70%Revenue growth targetBy FY27, company target
25%Export share targetBy FY27, company target
About ₹75 crExpansion project costCompany estimate, plus taxes
What management saidWhenWhat happened
UN qualification under way, with an export launch by the end of the then current year or in the first quarter of the nextOffer documentAt the May 2026 call the UN application was still pending; trial export orders had come from Kenya

Is it a good business? Six questions

Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.

Anondita Medicare makes condoms in Noida and earns its money from its own Cobra brand and from government family planning orders, and the company says the brand earns better margins.

Its weak spot is slow payment from government buyers and heavy spending on new lines, so cash from the business has trailed profit.

WatchCan it set its own prices?Much of the business is won on price. Government orders go to the lowest bidder, and the offer document says price decides most customer choices.
The evidence. Offer document: price is the deciding factor in most cases (p.183); government tenders usually go to the lowest bid, L1 (p.185). About 42% of FY26 sales were to government buyers (call, p.12).Offer document, p.183 and p.185; Earnings call transcript, May 2026, p.12
AverageHow strong is it against rivals?It makes and packs its own products and is strong in North India, but it is small next to national brands.
The evidence. Brickwork notes a dominant regional position in North India and in-house manufacturing as a cost advantage, but a smaller scale than larger peers and high competition from players such as Mankind Pharma and Durex.Credit rating note, May 2026, p.2 and p.3
WatchWho are its customers?Government buyers are the largest single group, alongside shops reached through its own subsidiary and distributors.
The evidence. About 42% of FY26 sales went to government buyers and 58% to the own brand (call, p.12). In FY25, government agencies and AIDS control societies bought ₹34.5 cr of the company's ₹60.5 cr standalone sales (offer document, p.180).Earnings call transcript, May 2026, p.12; Offer document, p.180
WatchDoes it need a lot of money?Yes. New lines cost a lot, and slow government payments tie up money in receivables.
The evidence. The chief financial officer put FY26 capital spending at about ₹62 cr (call, p.9); the ongoing expansion is estimated at about ₹75 cr plus taxes (presentation, p.12); trade receivables were ₹51.9 cr at March 2026 (presentation, p.37). Brickwork calls the business working capital intensive (p.2).Earnings call transcript, May 2026, p.9; Investor presentation, June 2026, p.12 and p.37; Credit rating note, May 2026, p.2
AverageCan it keep finding new work?It keeps winning government tenders at home and has new certificates for selling abroad, but the big export orders were not yet confirmed at the last call.
The evidence. Declared L1 in August 2026 for a Central Medical Services Society tender of 8,00,62,000 condoms (press release, p.2). MDSAP and SABS certificates in hand (annual report, p.13); the South African purchase order was pending and the UN application still in the pipeline at the May 2026 call (p.8 and p.9).Press release, September 2026, p.2; Annual report 2025-26, p.13; Earnings call transcript, May 2026, p.8 and p.9
AverageDo good and bad years swing a lot?Sales have grown each year so far, but they bunch up at the year end and latex costs move with the seasons.
The evidence. The chief financial officer said government sales are higher in the last quarter because budgets must be used within the year (call, p.12); FY26 revenue was ₹54.1 cr in the first half and ₹83.3 cr in the second. Brickwork notes latex price spikes in the rainy season (p.3).Earnings call transcript, May 2026, p.12; Credit rating note, May 2026, p.3

Who runs Anondita Medicare?

Promoters, directors and officers; tap a name for the background

AGAnupam GhoshPromoter and Managing Director · holds 61.99%

Has 25 years of experience in the healthcare products industry. Started in 1999 packing and selling contraceptives and gloves through the proprietorship M/s Healthcare Products, set up a condom plant in 2004, renamed the firm M/s Anondita Healthcare in 2013, and the company took over that business in 2024. Education: Senior Secondary (10+2).

Offer document, p.163 and p.210
SGSonia GhoshPromoter (Whole Time Director until 29 October 2025)

B.A. (Hons.) in Philosophy from Indraprastha College, New Delhi. Has 10 years of experience in administration and human resources and has been a director since 2014 at the group company Anondita Healthcare Products Private Limited. The offer document lists Sonia Ghosh as the wife of Anupam Ghosh and the mother of Reshant Ghosh. Resigned as Whole Time Director on 29 October 2025 (Annual report 2025-26, p.36).

Offer document, p.163, p.211 and p.215
RGReshant GhoshPromoter and Whole Time Director

Founder and Director of the subsidiary Anondita Healthcare and Rubber Products India Limited, with about three years of experience in marketing: market analysis, marketing strategy and building a network of distributors and retailers. Education: Senior Secondary (10+2).

Annual report 2025-26, p.16; Offer document, p.211
LSLakhinder SinghNon-Executive Director

Retired Government of India officer with over 36 years in taxation and revenue administration; served as Joint Secretary, Department of Revenue, Director General (Safeguards), Ministry of Finance, and Chief Commissioner, Customs and Central Excise, Meerut, with additional charge of Lucknow. M.A. in English Literature, B.I.T.S. Pilani.

Annual report 2025-26, p.17; Offer document, p.214
NGNishi GoelIndependent Director

Chartered Accountant and proprietor of M/s Nishi Goel & Associates, with experience in corporate law, direct and indirect taxation, auditing and accounting. Began in 2007 in the IT sector reviewing financial software and later worked at ICAI on putting XBRL in place in India.

Annual report 2025-26, p.16; Offer document, p.214
GKGaurav KumarIndependent Director

Qualified Company Secretary (ICSI) with over eight years of experience and proprietor of M/s K Gaurav & Co., consulting on corporate law and compliance in the real estate and NBFC sectors. Chairs the audit committee and the nomination and remuneration committee.

Annual report 2025-26, p.17

Anondita Medicare latest news and announcements

Announcements · Documents · Corporate actions

What changed recently

Each half-year is set against the same half a year earlier

  • H2 FY26: sales ₹83.3 cr (+81%), net profit ₹21.3 cr (+113%) on H2 FY25.
  • Shareholding, 24 Sept 2026: promoters 62.40% to 59.26%.

Anondita Medicare announcements

153 on record, latest first; each opens the filing on the exchange

Anondita Medicare annual reports, earnings calls and documents

Every document links to its source; “read” marks those this page is built from

Anondita Medicare share split, bonus and dividends

From the corporate actions the company announces on the exchange

  • Rights issueRIGHTS 97:1831 @ PREMIUM RS 940/-ex-date 2 Sept 2026
Checks we ran on Anondita Medicare's data · 9

Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.

  • ✓Balance sheet totals add up for FY25 and FY26.
  • ✓Market cap uses the share count in the latest shareholding pattern (1,90,44,784 shares).
  • !The FY26 results imply 1,80,90,000 shares at face value ₹10, which disagrees with the shareholding pattern; the pattern is used.
  • ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
  • ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
  • ✓The two half-years of FY26 add up to the full-year sales.
  • ✓Earnings per share moves in line with profit across the years shown.
  • ✓Revenue and profit are reported for every year shown, FY25 to FY26.
  • iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.

Questions people ask about Anondita Medicare

What does Anondita Medicare do?

Anondita Medicare makes condoms at its own plant in Noida and sells them under its own brand, Cobra, to shops in several states and to government health programmes. Its shares trade on NSE Emerge.

What is the share price of Anondita Medicare?

₹1,038 at the close on 19 Nov 2026, from the exchange's daily figures.

What is the market cap of Anondita Medicare?

₹1,978 cr at the close on 19 Nov 2026, on 1,90,44,784 shares.

What is the P/E of Anondita Medicare?

57.7 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).

What are Anondita Medicare's revenue and profit?

Revenue ₹137 cr and profit after tax ₹34 cr in FY26.

Who are the promoters of Anondita Medicare?

Anupam Ghosh, Sonia Ghosh, Reshant Ghosh; promoters held 59.26% at 24 Sept 2026.

What was the IPO price of Anondita Medicare?

₹145 a share; it listed on 1 Sept 2025.

What is Anondita Medicare's website?

www.anonditamedicare.com

More SME companies like Anondita Medicare

Other listed SME companies in personal products, the closest in size first, each read from its own documents.

Every listed SME company in Personal Products → · SME companies listed in 2025 →

Built from 3 earnings call transcripts, 3 investor presentations, 3 press releases, 2 annual reports, 2 credit rating notes, 1 offer document, 1 result filing, 153 exchange announcements, 3 shareholding patterns and 2 years of reported results. Every figure carries its source; where the documents are silent, the page says so.